Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it received a ‘milestone payment’ from an unnamed pharmaceutical partner following the first commercial sale of its AT220 product. Chief Executive Officer Sarah Howell says: ‘The commercialisation of this product in Europe, the first to be launched incorporating our Arestat technology, is a significant milestone for Arecor and further demonstrates the strength of our Arestat platform and the value it can bring to our partners and ultimately patients.’
Current stock price: 184.95 pence, up 1.3%
12-month change: down 25%
Copyright 2023 Alliance News Ltd. All Rights Reserved.